Dusseldorf - Delayed Quote EUR

Eli Lilly and Co (LLY.DU)

758.10

+9.10

+(1.21%)

As of 4:31:01 PM GMT+2. Market Open.

Analysts Maintain Buy Ratings on Eli Lilly Stock (LLY) as Q1 Earnings Loom

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the stock. Despite broader market uncertainties, the company’s robust performance in the diabetes and obesity segments, particularly with GLP-1 drugs like Mounjaro and Zepbound, has bolstered analysts’ confidence. Overall, Wall Street expects an EPS (earnings per share) of $4.17, significantly higher than the $2.58 in Q1 2024. Notably, GLP-1 drugs help regulate b

TipRanks 3 hours ago

LLY
AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 2.93% and 3.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 hours ago

ABBV

LLY
The Best Stock to Buy With Less Than $60 in the Market Sell-Off

One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for just $60 each, and as recently as last July, traded in the mid-140s. Novo Nordisk is an outstanding business to own for this amount, even considering the recent issues it has faced. There can also be disadvantages in overreliance on a single therapeutic area, and Novo Nordisk has long focused on endocrine-related disorders.

Motley Fool 6 hours ago

NVO

LLY
Trending tickers: Alphabet, Intel, Meta, Novo Nordisk and WPP

The latest investor updates on stocks that are trending on Friday.

Yahoo Finance UK 6 hours ago

GOOG

LLY

META
Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

Earnings preview of key companies reporting next week and what to look out for.

Yahoo Finance UK 11 hours ago

KHC

PUGBY

PUIGF
PFE vs. LLY: Which Stock Should Value Investors Buy Now?

PFE vs. LLY: Which Stock Is the Better Value Option?

Zacks yesterday

LLY

PFE
Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs

RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 guidance.

Zacks yesterday

ROG.SW

LLY
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.

Zacks yesterday

NVO

LLY
Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.

Eli Lilly said in a news release that its orforglipron pill had passed a Phase 3 trial with “statistically significant efficacy results” and a safety profile consistent with injectable obesity drugs that already are on the market. Orforglipron is a GLP-1 receptor agonist that works similarly to medications like Novo’s Ozempic. The pill mimics the effects of the hormone glucagon-like peptide-1, which plays a role in regulating appetite and blood sugar levels.

Barrons.com yesterday

LLY
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks yesterday

LLY

PFE
Jim Cramer Calls Eli Lilly and Company (LLY) a ‘Game Changer’ After Obesity Pill Trial Success

We recently published a list of Jim Cramer Says Trump’s Fed Chair Tussle Is Like “The Godfather” & Discusses These 10 Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discussed. In a recent appearance on CNBC’s Squawk on […]

Insider Monkey yesterday

LLY
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing

The lawsuit filings are the latest turn in a long-running legal saga between GLP-1RAs makers and compounders.

Pharmaceutical Technology yesterday

LLY
Eli Lilly is stepping up its fight against copycat weight loss drugs

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss drugs Mounjaro and Zepbound.

Quartz 2 days ago

LLY
Top Midday Stories: Boeing to Ask FAA to Lift Production Cap; Musk Says His Government Commitment to 'Drop Significantly'

All three major US stock indexes were up sharply, with the Nasdaq Composite gaining nearly 3% in lat

PREMIUM
MT Newswires 2 days ago

BA

LLY

TSLA
Is Eli Lilly and Company (LLY) the Best Stock That Will Always Grow?

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming […]

Insider Monkey 2 days ago

LLY
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound's prospects still look bright, but some recent developments point to another weight loss drug that could become yet another powerful growth driver for Lilly.

Motley Fool 2 days ago

LLY
Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.

Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (NYSE: LLY) stock cut his price target on the pharmaceutical giant. On Thursday morning, BMO Capital's Evan David Seigerman made his move on Eli Lilly. While Seigerman waxed bullish about the company's hottest product at the moment (obesity drug Zepbound), he expressed concerns about the broader macroeconomic environment.

Motley Fool 2 days ago

LLY
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results -- though strong by comparison to most of its peers -- haven't been as good as investors expected. The company has also faced clinical trial setbacks: An otherwise promising weight loss medicine it developed failed to impress the market with its late-stage results.

Motley Fool 2 days ago

NVO

LLY
Lilly sues four compounders over copies of weight-loss drugs

Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss and diabetes medicines. Compounders were, until recently, allowed to produce copies of obesity drugs while the FDA classified them as being in shortage, under U.S. rules that permit such manufacturing only during supply gaps. Tirzepatide is the main ingredient in Lilly's weight-loss and diabetes medicines, including the blockbuster, Mounjaro.

Reuters 2 days ago

LLY
Is Eli Lilly Stock a Buy?

The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up.

Motley Fool 2 days ago

LLY

NVO

Performance Overview

Return	LLY.DU	S&P 500 (^GSPC)
YTD	+1.64%	-6.44%
1-Year	+13.46%	+9.01%
3-Year	+198.53%	+28.09%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Co (LLY.DU)

Analysts Maintain Buy Ratings on Eli Lilly Stock (LLY) as Q1 Earnings Loom

AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates

The Best Stock to Buy With Less Than $60 in the Market Sell-Off

Trending tickers: Alphabet, Intel, Meta, Novo Nordisk and WPP

Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs

Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

Eli Lilly Stock Soars on Weight-Loss News. Why It’s Bad for Novo Nordisk.

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Jim Cramer Calls Eli Lilly and Company (LLY) a ‘Game Changer’ After Obesity Pill Trial Success

Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing

Eli Lilly is stepping up its fight against copycat weight loss drugs

Top Midday Stories: Boeing to Ask FAA to Lift Production Cap; Musk Says His Government Commitment to 'Drop Significantly'

Is Eli Lilly and Company (LLY) the Best Stock That Will Always Grow?

Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug

Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.

Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?

Lilly sues four compounders over copies of weight-loss drugs

Is Eli Lilly Stock a Buy?

Performance Overview